DE69738709D1 - Herpes simplex virusstaemme - Google Patents

Herpes simplex virusstaemme

Info

Publication number
DE69738709D1
DE69738709D1 DE69738709T DE69738709T DE69738709D1 DE 69738709 D1 DE69738709 D1 DE 69738709D1 DE 69738709 T DE69738709 T DE 69738709T DE 69738709 T DE69738709 T DE 69738709T DE 69738709 D1 DE69738709 D1 DE 69738709D1
Authority
DE
Germany
Prior art keywords
icp27
icp4
icp0
icp22
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738709T
Other languages
English (en)
Inventor
Neal A Deluca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24612790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69738709(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Application granted granted Critical
Publication of DE69738709D1 publication Critical patent/DE69738709D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C12N2710/16652—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
DE69738709T 1996-05-22 1997-05-22 Herpes simplex virusstaemme Expired - Lifetime DE69738709D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/651,419 US5804413A (en) 1992-07-31 1996-05-22 Herpes simplex virus strains for gene transfer
PCT/US1997/008681 WO1998015637A1 (en) 1996-05-22 1997-05-22 Herpes simplex virus strains

Publications (1)

Publication Number Publication Date
DE69738709D1 true DE69738709D1 (de) 2008-07-03

Family

ID=24612790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738709T Expired - Lifetime DE69738709D1 (de) 1996-05-22 1997-05-22 Herpes simplex virusstaemme

Country Status (8)

Country Link
US (1) US5804413A (de)
EP (1) EP0904395B2 (de)
JP (1) JP2001503611A (de)
AT (1) ATE396274T1 (de)
AU (1) AU733945B2 (de)
CA (1) CA2255939A1 (de)
DE (1) DE69738709D1 (de)
WO (1) WO1998015637A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223411B1 (en) * 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US6261552B1 (en) * 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
GB9816856D0 (en) * 1998-08-03 1998-09-30 Univ London Cell lines for virus growth
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
WO2001010903A2 (en) * 1999-08-09 2001-02-15 Incyte Genomics, Inc. Proteases and protease inhibitors
CA2384650A1 (en) * 1999-09-10 2001-03-15 Incyte Genomics, Inc. Apoptosis proteins
US6660259B2 (en) * 1999-12-08 2003-12-09 Onyx Pharmaceuticals, Inc. Herpes simplex virus for treating unwanted hyperproliferative cell growth
GB0001476D0 (en) * 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
WO2001066742A2 (en) * 2000-03-03 2001-09-13 Incyte Genomics, Inc. G-protein coupled receptors
US20040086877A1 (en) 2000-06-16 2004-05-06 Lal Preeti G. Multi-mode directi memory access controller and method
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
EP1346036B1 (de) * 2000-11-29 2010-04-28 University of Rochester Helfervirus-freie herpesvirus-amplifikatpartikel und deren verwendungen
US8092791B2 (en) 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
WO2003006658A1 (en) * 2001-07-13 2003-01-23 The General Hospital Corporation Mutant herpes simplex virus that expresses yeast cytosine deaminase
US7378492B2 (en) * 2002-02-20 2008-05-27 Incyte Corporation CD40-related receptor that binds CD40L
ATE514430T1 (de) * 2002-04-25 2011-07-15 Shire Human Genetic Therapies Behandlung des alpha-galactosidase a mangels
WO2004015396A2 (en) * 2002-08-13 2004-02-19 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
WO2004033636A2 (en) * 2002-10-04 2004-04-22 Incyte Corporation Protein modification and maintenance molecules
US20050164275A1 (en) * 2002-10-18 2005-07-28 Incyte Corporation Phosphodiesterases
WO2004044166A2 (en) * 2002-11-12 2004-05-27 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
US20070009516A1 (en) * 2002-11-26 2007-01-11 Tran Uyen K Immune response-associated proteins
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US7829682B1 (en) 2003-04-30 2010-11-09 Incyte Corporation Human β-adrenergic receptor kinase nucleic acid molecule
EP2377882A1 (de) 2004-10-28 2011-10-19 University of Pittsburgh of the Commonwealth System of Higher Education Peripher verabreichte Gentherapie mit Glutaminsäure-Decarboxylase gegen Schmerzen aufgrund einer Rückenmarksverletzung
WO2006130806A2 (en) * 2005-06-01 2006-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Assay for agonists and antagonists of ion channels and for regulators of genetic expression
WO2006132925A2 (en) * 2005-06-01 2006-12-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
US20100008944A1 (en) * 2005-07-29 2010-01-14 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
EP1783210A1 (de) * 2005-11-08 2007-05-09 ProBioGen AG Proteinfaktoren zur Erhöhung der Produktivität, neue Zelllinien und deren Verwendungen
US20080289058A1 (en) * 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US8889622B2 (en) * 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
EP3284821B1 (de) 2010-03-23 2022-01-05 Precigen, Inc. Vektoren zur bedingten expression therapeutischer proteine, wirtszellen mit diesen vektoren und verwendungen davon
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
EP3450568A3 (de) 2011-03-04 2019-04-24 Intrexon Corporation Vektoren für bedingte proteinexpression
RU2020105656A (ru) * 2013-07-17 2021-01-27 Юниверсити Оф Питтсбург- Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Нетоксичные векторы на основе впг для применений в эффективной доставке генов и комплементирующие клетки для их продуцирования
KR102490462B1 (ko) 2013-10-28 2023-01-19 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양분해성 hsv 벡터
US9580699B2 (en) 2014-04-17 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library
CN107073091A (zh) 2014-09-07 2017-08-18 西莱克塔生物科技公司 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
CA2985649A1 (en) * 2015-05-13 2016-11-17 Sanofi Pasteur Biologics, Llc Icp0-mediated enhanced expression system
ES2919953T3 (es) 2016-01-27 2022-07-29 Oncorus Inc Vectores víricos oncolíticos y usos de los mismos
EP3432912B1 (de) * 2016-03-25 2022-12-21 PeriphaGen, Inc. Hochumformende hsv-vektoren
US10799560B2 (en) 2016-03-25 2020-10-13 Periphagen, Inc. HSV vectors for delivery of NT3 and treatment of CIPN
EP3478321A4 (de) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotypisierte onkolytische virale verabreichung von therapeutischen polypeptiden
CA3034094A1 (en) 2016-08-16 2018-02-22 Bluebird Bio, Inc. Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
EP3504335A4 (de) 2016-08-23 2020-04-15 Bluebird Bio, Inc. Tim3-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
KR102622910B1 (ko) 2016-09-08 2024-01-10 2세븐티 바이오, 인코포레이티드 Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
US11530395B2 (en) 2016-10-17 2022-12-20 2Seventy Bio, Inc. TGFBetaR2 endonuclease variants, compositions, and methods of use
AU2017362484B2 (en) 2016-11-17 2021-12-16 2Seventy Bio, Inc. TGFβ signal convertor
KR20240015743A (ko) 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
WO2018152325A1 (en) 2017-02-15 2018-08-23 Bluebird Bio, Inc. Donor repair templates multiplex genome editing
WO2018176103A1 (en) 2017-03-30 2018-10-04 The University Of Queensland "chimeric molecules and uses thereof"
JP7191042B2 (ja) 2017-05-25 2022-12-16 ２セブンティ バイオ インコーポレイテッド Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
WO2019070974A1 (en) 2017-10-04 2019-04-11 Bluebird Bio, Inc. PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
US20190142974A1 (en) 2017-10-13 2019-05-16 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
EP3758682A4 (de) 2018-02-26 2021-12-15 Antolrx, Inc. Tolerogene liposome und verfahren zur verwendung davon
KR20210021522A (ko) 2018-06-14 2021-02-26 블루버드 바이오, 인코포레이티드. Cd79a 키메라 항원 수용체
EP3856761A1 (de) * 2018-09-24 2021-08-04 Krystal Biotech, Inc. Zusammensetzungen und verfahren zur behandlung des netherton-syndroms
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
US20200291428A1 (en) * 2019-03-14 2020-09-17 Massachusetts Institute Of Technology Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof
US20200360453A1 (en) 2019-04-28 2020-11-19 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
US20220380735A1 (en) 2019-10-10 2022-12-01 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
KR20220167324A (ko) 2020-04-10 2022-12-20 솔라 바이오사이언시즈 엘엘씨 단백질 응집 장애의 치료를 위한 조성물 및 방법
KR20230025659A (ko) 2020-04-28 2023-02-22 솔라 바이오사이언시즈 엘엘씨 Tdp-43 단백질병증의 치료를 위한 조성물 및 방법
US20230234997A1 (en) 2020-06-05 2023-07-27 Sola Biosciences Llc Compositions and Methods for the Treatment of Synucleinopathies
JP2023529892A (ja) 2020-06-09 2023-07-12 イノザイム ファーマ インク． 可溶性ｅｎｐｐ１又はｅｎｐｐ３タンパク質及びその使用
TW202233655A (zh) 2020-10-26 2022-09-01 美商碩拿生物科學有限責任公司 用於治療阿茲海默症之組合物及方法
WO2023288267A1 (en) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023060248A1 (en) 2021-10-08 2023-04-13 Sola Biosciences Llc Compositions and methods for the treatment of p53-mediated cancers
WO2023060221A2 (en) 2021-10-08 2023-04-13 Sola Biosciences Llc Compositions and methods for the treatment of proteopathies
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026635A (en) * 1987-05-19 1991-06-25 Du Pont Merck Pharmaceutical Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
US5674722A (en) * 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
AU1176095A (en) * 1993-11-10 1995-05-29 University Of British Columbia, The Method of treatment using, process of preparing, and composition comprising a recombinant hsv-1
US5698431A (en) * 1995-02-09 1997-12-16 Washington University Herpes simplex virus mutant UL41NHB

Also Published As

Publication number Publication date
JP2001503611A (ja) 2001-03-21
ATE396274T1 (de) 2008-06-15
AU733945B2 (en) 2001-05-31
US5804413A (en) 1998-09-08
EP0904395A1 (de) 1999-03-31
CA2255939A1 (en) 1998-04-16
WO1998015637A1 (en) 1998-04-16
EP0904395B1 (de) 2008-05-21
AU3137997A (en) 1998-05-05
EP0904395B2 (de) 2011-07-27

Similar Documents

Publication Publication Date Title
DE69738709D1 (de) Herpes simplex virusstaemme
HUP9802538A2 (hu) Vektorok és eljárások helyspecifikus rekombináció előidézésére
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
EP1923467A3 (de) Adenovirusvektoren für die Gentherapie
DE3585900D1 (en) Enhancer fuer eukaryotische expressionssysteme.
WO1995027071A3 (en) An adenovirus supervector system
GB9709728D0 (en) Single step method
NO964445D0 (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
WO1997005255A3 (fr) Virus auxiliaires pour la preparation de vecteurs viraux recombinants
CA2063427A1 (en) Rapid, versatile and simple system for expressing genes in eukaryotic cells
ES2255281T3 (es) Sobreexpresion de genes de fitasa en sistmas de levadura.
CA2179656A1 (en) Chromosomal expression of heterologous genes in bacterial cells
Leiden et al. Identification of the herpes simplex virus DNA sequences present in six herpes simplex virus thymidine kinase-transformed mouse cell lines
CA2263713A1 (en) Lyophilization of cultured human cells to preserve rna and dna
HUP9700429A2 (en) Nucleic acid constructs for the cell cycleregulated expression of genes, cells containing such constructs and their use for preparing drugs
FI962268A0 (fi) Homologinen, rekombinanttinen vasta-aineilmentämisjärjestelmä rottien tai hiirien soluille
IE840258L (en) Expression of gene products.
MXPA98003564A (es) Genes de des-epoxidasa de violaxantina de planta ysus metodos relacionados.
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
DK0843731T3 (da) Adenovirusvektorer til genterapi
BR9711998A (pt) Herpesvìrus saimiri como vetor viral.
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
PT1212428E (pt) Redireccionamento da expressao do gene gama 34.5 de herpes atraves de um promotor especifico de celulas e/ou especifico de tumores
AU2362795A (en) Introduction of HIV-protective genes into cells by particle-mediated gene transfer
Wagner et al. Photoreactivation of herpes simplex virus in human fibroblasts

Legal Events

Date Code Title Description
8363 Opposition against the patent